Industry News
Biotechnology Industry News
The first woman to helm a Big…
The first woman to helm a Big Pharma will be stepping down in January as GSK’s Emma Walmsley moves aside for her chief commercial officer Luke Miels. Walmsley, 56, who became the British pharma’s CEO
An AI-driven drug discovery…
An AI-driven drug discovery platform will receive a step up onto the Nasdaq via a reverse merger with a blank check company.
89bio has set out the journey…
89bio has set out the journey that led it from talks with a long list of drugmakers to weeks of negotiations with Roche to iron out the details of a deal worth up to $3.5 billion.
Bolt Biotherapeutics has halved…
Bolt Biotherapeutics has halved its workforce for the second time in two years as the oncology biotech delays a readout of its lead immunotherapy.
Takeda is tapping out of the cell…
Takeda is tapping out of the cell therapy arena as part of a strategic portfolio reprioritization, the Japanese drugmaker announced on Oct. 1, becoming the latest Big Pharma to back away from the modality.
After axing billions in biomedical…
After axing billions in biomedical research grants and pulling the plug on a pediatric brain tumor consortium, the federal government has announced plans to double funding for an artificial intelligence-driven data effort for kids with
The FDA issued a complete response…
The FDA issued a complete response letter in response to Zydus's bid to commercialize the first approved treatment for rare, often fatal pediatric disease Menkes disease.
Astex Pharmaceuticals, Bristol…
Astex Pharmaceuticals, Bristol Myers Squibb and Takeda have agreed to pool data to support work on an AI model, joining AbbVie and Johnson & Johnson on the starry list of participants in the program.
Aerska has launched with $21…
Aerska has launched with $21 million in seed funding that the Ireland and U.K.-based biotech will use for its mission to deliver genetic medicines to the brain.
Kyorin Pharmaceutical has…
Kyorin Pharmaceutical has strengthened its autoimmune portfolio by paying $10 million upfront for the Japan rights to Hinge Bio’s preclinical lupus drug.
Japanese biotech Heartseed said it…
Japanese biotech Heartseed said it was "difficult to reasonably foresee" that Novo would scrap the 2021 deal, despite its ongoing restructuring around a strategic focus on diabetes and obesity.
Unifying data and processes across…
Unifying data and processes across the financial lifecycle can simplify work, enable faster site payments and shorten timelines.
U.S.-based Barinthus…
U.S.-based Barinthus Biotherapeutics is entering a reverse merger with U.K. biotech Clywedog Therapeutics, with the combined company expected to advance three clinical assets across diabetes and autoimmune disease.
AnaptysBio plans to split into two…
AnaptysBio plans to split into two publicly traded companies, with one entity taking forward the biopharma’s clinical-stage pipeline and the other overseeing its royalty-based agreements.
Opus Genetics has shared data on…
Opus Genetics has shared data on its gene therapy in children with an ultrarare eye disease, setting the biotech up to talk to the FDA about the next steps for the program.
The GLP-1 agonist at the center of…
The GLP-1 agonist at the center of Pfizer’s upfront $4.9 billion buyout of Metsera last week has been tied to 14.1% weight loss at 28 weeks as well as “potentially class-leading tolerability,” according to the
The layoffs aren’t letting up at…
The layoffs aren’t letting up at Sutro Biopharma. After halving the antibody-drug conjugate biotech’s head count in the spring, the company is waving goodbye to a third of its remaining workforce in the fall.
Accomplished oncologist Anthony…
Accomplished oncologist Anthony Letai, M.D., Ph.D., has been sworn in as the new leader of the NIH’s National Cancer Institute, the agency announced Sept. 29.
In this market, three things make…
In this market, three things make fundraising easier for a biotech: a derisked asset touting a well-defined profile and an experienced team to guide the program’s development.
After Harvard University scored a…
After Harvard University scored a recent legal victory over the Trump administration's “arbitrary and capricious" funding freeze orders, it appears the government is ready to go another route as it ramps up its confrontation with